Last reviewed · How we verify

treatments for essential tremor

US Department of Veterans Affairs · Phase 3 active Small molecule

This drug targets the GABA_A receptor to modulate neuronal excitability.

This drug targets the GABA_A receptor to modulate neuronal excitability. Used for Essential tremor.

At a glance

Generic nametreatments for essential tremor
SponsorUS Department of Veterans Affairs
Drug classGABA_A receptor modulator
TargetGABA_A receptor
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

By enhancing GABAergic transmission, it reduces neuronal hyperexcitability and tremor severity. This is achieved through the drug's action on the GABA_A receptor, a key component of the inhibitory neurotransmission system.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: